| Literature DB >> 32722320 |
Leila Motlagh Scholle1, Helena Schieffers1, Samiya Al-Robaiy2, Annemarie Thaele1, Faramarz Dehghani3, Diana Lehmann Urban4, Stephan Zierz1.
Abstract
Mitochondrial function is essential for ATP-supply, especially in response to different cellular stressors. Increased mitochondrial biogenesis resulting from caloric restriction (CR) has been reported. Resveratrol (RSV) is believed to mimic the physiological effects of CR mainly via a sirtuin (SIRT) 1-dependent pathway. The effect of RSV on the physiological function of mitochondrial respiratory complexes was evaluated using a Seahorse XF96. Myoblasts of five patients harboring the m.3243A>G mutation and five controls were analyzed. The relative expression of several genes involved in mitochondrial biogenesis was evaluated for a better understanding of the coherent mechanisms. Additionally, media-dependent effects of nutritional compounds and hormonal restrictions (R) on myoblasts from patients and controls in the presence or absence of RSV were investigated. Culturing of myoblasts under these conditions led to an upregulation of almost all the investigated genes compared to normal nutrition. Under normal conditions, there was no positive effect of RSV on mitochondrial respiration in patients and controls. However, under restricted conditions, the respiratory factors measured by Seahorse were improved in the presence of RSV. Further studies are necessary to clarify the involved mechanisms and elucidate the controversial effects of resveratrol on SIRT1 and SIRT3 expression.Entities:
Keywords: OXPHOS; SIRT1; SIRT3; m.3243A>G mutation; resveratrol
Year: 2020 PMID: 32722320 PMCID: PMC7464358 DOI: 10.3390/biom10081103
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Figure 1Schematic diagram showing the investigated pathways in the present study using RSV in patients and controls, adopted accordingly [21]. Caloric restriction (CR) activates the SIRT1 levels or NAD+ levels leading to the activation of PGC-1α in the nucleus, which then activates the transcription of genes that are necessary for mitochondrial function and biogenesis. CR also leads to activation of AMPK and, therefore, the activation of PGC-1α in skeletal muscle. RSV: Resveratrol; NAD: Nicotinamide adenine dinucleotide; SIRT1: sirtuin 1; SIRT3: sirtuin 3; PGC-1α: peroxisome proliferator-activated receptor gamma co-activator 1α; Nrf1: Nuclear Respiratory Factor 1; Tfam: Mitochondrial Transcription Factor A.
Sex, age, and location of muscle biopsy of five patients with the genetically confirmed m.3243A>G mutation and five healthy controls, F: female, M: male.
| Gender | Age at Biopsy | Location of Muscle Biopsy | |
|---|---|---|---|
|
| |||
| P 1 | M | 43 | biceps brachii muscle |
| P 2 | M | 42 | biceps brachii muscle |
| P 3 | F | 70 | quadriceps muscle |
| P 4 | M | 34 | deltoideus muscle |
| P 5 | F | 40 | biceps brachii muscle |
|
| |||
| C1 | F | 50 | biceps brachii muscle |
| C 2 | M | 53 | quadriceps muscle |
| C 3 | F | 40 | quadriceps muscle |
| C 4 | M | 35 | biceps brachii muscle |
| C 5 | F | 49 | biceps brachii muscle |
Primers used for quantitative RT-PCR.
| Target Gene | Forward Primer | Reverse Primer |
|---|---|---|
|
| AGAAGAACCCATGGAGGATG | TCATCTCCATCAGTCCCAAA |
|
| CAGCAGTACGATCTCCCGTA | GAAGCAGCCGGAGAAAGTAG |
|
| GTCCAGGCAGGAGCTTTTAGA | AGCTTTGATTTGCTCAAGCCAT |
|
| AGGAACACGGAGTGACCCAA | TATGCTCGGTGTAAGTAGCCA |
|
| ATGGCGTTTCTCCGAAGCAT | TCCGCCCTATAAGCATCTTGA |
|
| ACCAGTCAACAGGGGACATAA | CTTCGTGGGGTCCTTTTCACC |
|
| GCGCCGTTCCGAAAGTTG | CGCGCCGCTGGGTTTTATAG |
Figure 2Evaluation of mitochondrial function using a Seahorse XF96 Cell Analyzer in myoblasts from patients (n = 5) and controls (n = 5). The key parameters of mitochondrial function such as basal respiration (BR), ATP production (ATP-R) and spare respiratory capacity (SRC) were analyzed as previously described. (A) Basal respiration (BR), (B) maximal respiration (MR), (C) spare respiratory capacity (SRC) and (D) ATP-linked respiration (ATP-R) after 48 h under normal (N) and restricted (R) conditions. The significant differences are shown in Table 3 and Table 4, and Table S1.
Comparison of the mean values of the key parameters for mitochondrial function (basal, MR, ATP production and SRC) using a Seahorse XF96 Cell Analyzer in myoblasts between patients (n = 5) and controls (n = 5) under normal (N) or restricted (R) conditions. p values are only shown in the case of significant differences between patients and controls. −RSV = without RSV.
|
| |||||||||
|
|
|
| |||||||
| Controls (mean) | Patients (mean) | Controls (mean) | Patients (mean) | Controls (mean) | Patients (mean) | ||||
| Basal | 59.24 | 41.71 | 0.0005 | 56.11 | 39.19 | <0.0001 | 45.44 | 35.44 | 0.05 |
| MR | 212.3 | 153.3 | 0.05 | 191.3 | 169.2 | 190.4 | 164 | ||
| SRC | 156.4 | 144.1 | 135.2 | 115.8 | 137.3 | 116.8 | |||
| ATP | 45.64 | 33.51 | 0.01 | 40.39 | 28.82 | 0.001 | 37.24 | 29.4 | 0.03 |
|
| |||||||||
|
|
|
| |||||||
| Controls (mean) | Patients (mean) | Controls (mean) | Patients (mean) | Controls (mean) | Patients (mean) | ||||
| Basal | 14.19 | 16.52 | 18.91 | 23.8 | 24.84 | 21 | |||
| MR | 78.04 | 66.87 | 87.21 | 81.92 | 103.8 | 71.5 | |||
| SRC | 57.88 | 50.34 | 68.79 | 62.84 | 79.22 | 48.38 | |||
| ATP | 10.67 | 12.45 | 18.9 | 23.8 | 24.84 | 21 | |||
Comparison of the effect of 10 or 20 µM RSV on basal, MR, ATP production, and SRC measured under normal (N) or restricted (R) conditions in patients (n = 5) and controls (n = 5). p values are only shown in the case of a significant difference between the two conditions.
|
| ||||||||||
|
|
| |||||||||
| −RSV | 10 | 20 | −RSV | 10 | 20 | |||||
| Basal | 59.24 | 56.11 | 45.44 | 0.02 | 14.19 | 18.91 | 24.84 | 0.008 | ||
| MR | 212.3 | 191.3 | 190.4 | 78.04 | 87.21 | 103.8 | ||||
| SRC | 156.4 | 135.2 | 137.3 | 57.88 | 68.79 | 79.22 | ||||
| ATP | 45.64 | 40.39 | 37.24 | 10.67 | 18.9 | 0.03 | 24.84 | <0.0001 | ||
|
| ||||||||||
|
|
| |||||||||
| −RSV | 10 | 20 | −RSV | 10 | 20 | |||||
| Basal | 41.71 | 39.19 | 35.44 | 16.52 | 23.8 | 0.05 | 21 | |||
| MR | 153.3 | 169.2 | 164 | 66.87 | 81.92 | 71.5 | ||||
| SRC | 144.1 | 115.8 | 116.8 | 50.34 | 62.84 | 48.38 | ||||
| ATP | 33.51 | 28.82 | 29.4 | 12.45 | 23.8 | <0.0001 | 21 | 0.005 | ||
Comparison of the relative expression rate of the genes SIRT1, SIRT3, PGC-1α, Nrf1, and Tfam measured under N or R conditions in patients (n = 5) and controls (n = 5). p values are only shown in the case of significant differences between patients and controls. −RSV = without RSV.
|
| |||||||||
|
|
|
| |||||||
| N (mean) | R (mean) | N (mean) | R (mean) | N (mean) | R(mean) | ||||
| SIRT1 | 0.56 | 2.04 | 2.65 | 0.82 | 0.84 | 7.1 | <0.0001 | ||
| SIRT3 | 0.4 | 2.1 | 0.02 | 1.77 | 1.47 | 1.07 | 3.46 | 0.0003 | |
| PGC-1α | 0.3 | 17.8 | <0.0001 | 1.41 | 8.3 | <0.0001 | 0.45 | 19.97 | <0.0001 |
| Nrf1 | 0.57 | 1.87 | 2.68 | 0.77 | 0.007 | 1.16 | 3.51 | 0.0004 | |
| Tfam | 2.99 | 4.45 | 12.44 | 2.67 | <0.0001 | 4.96 | 7.55 | ||
|
| |||||||||
|
|
|
| |||||||
| N (mean) | R (mean) | N (mean) | R (mean) | N (mean) | R (mean) | ||||
| SIRT1 | 1.26 | 3.19 | 2.463 | 0.95 | 0.67 | 5.82 | <0.0001 | ||
| SIRT3 | 0.77 | 2.9 | 0.0009 | 1.49 | 1.36 | 0.57 | 1.45 | ||
| PGC-1α | 0.27 | 4.7 | 0.006 | 0.94 | 3.78 | 0.54 | 4.43 | 0.02 | |
| Nrf1 | 0.93 | 2.97 | 0.003 | 1.21 | 0.79 | 0.9 | 3.7 | <0.0001 | |
| Tfam | 2.71 | 4.4 | 8.34 | 2.27 | 0.0003 | 1.53 | 2.7 | ||
Figure 3Evaluation of gene expression in myoblasts from patients (n = 5) and controls (n = 5), analyzed as previously described. (A) SIRT1, (B) SIRT3, (C) PGC-1 α, (D) Nrf1, and (E) Tfam after 48 h, N vs. R conditions. The significant differences are shown in Table 5 and Table 6, and Table S2.
The effect of 10 or 20 µM RSV on the relative expression rate of the genes SIRT1, SIRT3, PGC-1α, Nrf1, and Tfam measured under normal (N) or restricted (R) conditions in patients (n = 5) and controls (n = 5). p values are only shown in the case of significant differences between the two conditions.
|
| ||||||||||
|
|
| |||||||||
| −RSV | 10 | 20 | −RSV | 10 | 20 | |||||
| SIRT1 | 0.56 | 2.65 | 0.84 | 2.04 | 0.82 | 7.1 | <0.001 | |||
| SIRT3 | 0.4 | 1.77 | 1.07 | 2.1 | 1.47 | 3.46 | ||||
| PGC-1α | 0.3 | 1.41 | 0.45 | 17.8 | 8.3 | <0.0001 | 19.97 | |||
| Nrf1 | 0.57 | 2.68 | 0.002 | 1.16 | 1.87 | 0.77 | 3.51 | 0.03 | ||
| Tfam | 2.99 | 12.44 | <0.0001 | 4.96 | 4.45 | 2.67 | 7.55 | |||
|
| ||||||||||
|
|
| |||||||||
| −RSV | 10 | 20 | −RSV | 10 | 20 | |||||
| SIRT1 | 1.26 | 2.463 | 0.67 | 3.19 | 0.95 | 5.82 | 0.02 | |||
| SIRT3 | 0.77 | 1.49 | 0.57 | 2.9 | 1.36 | 1.45 | ||||
| PGC-1α | 0.27 | 0.94 | 0.54 | 4.7 | 3.78 | 4.43 | ||||
| Nrf1 | 0.93 | 1.21 | 0.9 | 2.97 | 0.79 | 0.004 | 3.7 | |||
| Tfam | 2.71 | 8.34 | 0.004 | 1.53 | 4.4 | 2.27 | 2.7 | |||